Annual Report of Fredun Pharmaceuticals Limited for the Financial Year 2025-2026 including the Notice of the 39th Annual General Meeting of the Company scheduled to be held on Tuesday, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fredun Pharmaceuticals has filed its Annual Report for FY 2025-26 along with the notice of its 39th AGM to be held on June 30, 2026 via video conferencing. Key business items to be tabled at the AGM include adoption of audited financials, declaration of a 7% dividend on equity shares, and re-appointment of a retiring director. Major corporate actions proposed include increasing the authorised share capital from Rs. 10 crore to Rs. 50 crore and issuing bonus shares in a 2:1 ratio (two bonus shares for every one held) by capitalising free reserves and securities premium. The company is also seeking shareholder approval to raise its overall borrowing limit and investment/loan ceiling to Rs. 600 crore, approve related party transactions up to Rs. 1 crore per transaction, and ratify the cost auditor's remuneration of Rs. 1.25 lakh.
The proposed 2:1 bonus issue rewards existing shareholders by expanding the share base, though it will dilute per-share metrics. The sharp jump in authorised capital and the Rs. 600 crore borrowing/investment limits signal aggressive expansion plans, which could support growth but also increase leverage risk. Shareholders should review the annual report financials before approving these enabling resolutions at the AGM.